Windlas Biotech has released the audio recording of their Q4 FY26 results, with a detailed transcript expected soon. The discussion encompasses their financial performance, offering insights for both investors and analysts.

Windlas Biotech achieved a notable 19% increase in revenue, reaching INR 904 crore in the financial year of 2026. This impressive growth highlights the company's strong operational growth over the past year.

Windlas Biotech has successfully resolved recent labor disputes in Uttarakhand, leading to the normalization of their production activities.

Windlas Biotech announces a share buyback program, purchasing 4.7 lakh shares for ₹1,000 each according to SEBI regulations, implying an investment of around ₹4.7 crores in buying back their own shares.

Windlas Biotech will disclose its financial year 2026 results and potential dividends during a board meeting on May 21st. Share trading is currently suspended but will reopen after the results are declared, approximately 48 hours later.

Windlas Biotech announced plans for a share buyback, aiming to purchase approximately 470,000 shares at a face value of INR 5 each. This move indicates the company's confidence in its own performance and could potentially benefit existing shareholders by reducing the number of outstanding shares.

Windlas Biotech announces a buyback of 4.7 million shares at ₹1000 each, totaling approximately ₹47 crore. Notably, this buyback excludes shares held by promoters and the record date is set for April 24, 2026.

Windlas Biotech's board has approved a share buyback priced at ₹1,000 per share, suggesting the possibility of returning capital to its shareholders through a tender offer.

Windlas Biotech is planning a potential share buyback, with the board set to discuss it on April 17, 2026. Investors should note that trading activity will be suspended for 48 hours following the release of FY26 results due to SEBI insider trading regulations.